Jeremy Grantham's AMGN Position Overview
Jeremy Grantham (via Grantham, Mayo, Van Otterloo & Co. LLC) currently holds 4.6K shares of Amgen Inc. (AMGN) worth $1.31 M, representing 0.00% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Jeremy Grantham has maintained a long-term strategic position in AMGN, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2013, adding 602.5K shares. Largest reduction occurred in Q3 2014, reducing 1.3M shares.
Analysis based on 13F filings available since 2013 Q2
Jeremy Grantham's Amgen (AMGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Amgen (AMGN) Trades by Jeremy Grantham
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +2.07 M | Add 0.00% | 2.07 M | $98.66 |
| Q3 2013 | +602,464 | Add 29.16% | 2.67 M | $111.94 |
| Q4 2013 | +453,895 | Add 17.01% | 3.12 M | $114.16 |
| Q1 2014 | +167,503 | Add 5.36% | 3.29 M | $123.34 |
| Q2 2014 | -29,329 | Reduce 0.89% | 3.26 M | $118.37 |
| Q3 2014 | -1.27 M | Reduce 38.91% | 1.99 M | $140.46 |
| Q4 2014 | -965,869 | Reduce 48.49% | 1.03 M | $159.29 |
| Q1 2015 | -526,304 | Reduce 51.29% | 499,847 | $159.85 |
| Q2 2015 | +129,113 | Add 25.83% | 628,960 | $153.52 |
| Q3 2015 | -49,534 | Reduce 7.88% | 579,426 | $138.32 |
| Q4 2015 | -223,563 | Reduce 38.58% | 355,863 | $162.33 |
| Q1 2016 | -201,848 | Reduce 56.72% | 154,015 | $149.93 |
| Q2 2016 | -151,216 | Reduce 98.18% | 2,799 | $152.20 |
| Q3 2016 | -400 | Reduce 14.29% | 2,399 | $166.74 |
| Q4 2016 | +100 | Add 4.17% | 2,499 | $146.06 |
| Q1 2017 | -499 | Reduce 19.97% | 2,000 | $164.00 |
| Q2 2017 | +200 | Add 10.00% | 2,200 | $172.27 |
| Q4 2017 | -200 | Reduce 9.09% | 2,000 | $174.00 |
| Q1 2018 | +4,900 | Add 245.00% | 6,900 | $170.43 |
| Q2 2018 | +2,400 | Add 34.78% | 9,300 | $184.62 |
| Q3 2018 | +132,500 | Add 1424.73% | 141,800 | $207.29 |
| Q4 2018 | +800 | Add 0.56% | 142,600 | $194.67 |
| Q1 2019 | -7,800 | Reduce 5.47% | 134,800 | $189.98 |
| Q2 2019 | -2,800 | Reduce 2.08% | 132,000 | $184.28 |
| Q3 2019 | -55,400 | Reduce 41.97% | 76,600 | $193.51 |
| Q4 2019 | -13,200 | Reduce 17.23% | 63,400 | $241.07 |
| Q1 2020 | +1,131 | Add 1.78% | 64,531 | $202.72 |
| Q2 2020 | -17,952 | Reduce 27.82% | 46,579 | $235.86 |
| Q3 2020 | -2,700 | Reduce 5.80% | 43,879 | $254.15 |
| Q4 2020 | -43,879 | Sold Out | 43,879 | $0.00 |
| Q3 2024 | +3,509 | New Buy | 3,509 | $322.21 |
| Q4 2024 | +928 | Add 26.45% | 4,437 | $260.64 |
| Q1 2025 | -673 | Reduce 15.17% | 3,764 | $311.55 |
| Q2 2025 | +481 | Add 12.78% | 4,245 | $279.21 |
| Q3 2025 | +397 | Add 9.35% | 4,642 | $282.20 |
Jeremy Grantham's Amgen Investment FAQs
Jeremy Grantham first purchased Amgen Inc. (AMGN) in Q2 2013, acquiring 2,066,387 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham has held Amgen Inc. (AMGN) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham's largest addition to Amgen Inc. (AMGN) was in Q2 2013, adding 2,066,387 shares worth $203.87 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Jeremy Grantham's firm, Grantham, Mayo, Van Otterloo & Co. LLC, owns 4,642 shares of Amgen Inc. (AMGN), valued at approximately $1.31 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Amgen Inc. (AMGN) represents approximately 0.00% of Jeremy Grantham's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham's peak holding in Amgen Inc. (AMGN) was 3,290,249 shares, as reported at the end of Q1 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.